Clinuvel Pharmaceuticals Limited
ASX: CUV
Clinuvel Shines with Strong Growth and Solid Balance Sheet
(Source: TradingView) 3-Month Performance Profile of CUV on a DTF compared to ASX 200 (XJO)
Clinuvel Pharmaceuticals delivered a strong first-half performance, with revenue up 10.5% to $35.65 million and underlying pre-tax earnings rising 48.1% to $21.93 million. Net profit after tax also grew 28.
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
